Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
NiKang Therapeutics
company
About
NiKang Therapeutics is a biotech company focused on discovering and developing small molecule oncology medicines.
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $50M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2017
- Number Of Employee
- 11 - 50
- Operating Status
- Active
NiKang Therapeutics is an early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Its discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$250M
NiKang Therapeutics has raised a total of
$250M
in funding over 2 rounds. Their latest funding was raised on
May 26, 2021 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 26, 2021 | Series C | $200M | 2 | — | — | Detail |
| Sep 14, 2020 | Series B | $50M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
3
NiKang Therapeutics is funded by 3 investors.
Lilly Asia Ventures
and Pavilion Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Lilly Asia Ventures
|
— | Series C |
Pavilion Capital
|
— | Series C |
|
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
